CN104432026A - 一种氨基酸组合物及其制备方法和应用 - Google Patents
一种氨基酸组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN104432026A CN104432026A CN201410628908.7A CN201410628908A CN104432026A CN 104432026 A CN104432026 A CN 104432026A CN 201410628908 A CN201410628908 A CN 201410628908A CN 104432026 A CN104432026 A CN 104432026A
- Authority
- CN
- China
- Prior art keywords
- mass parts
- acid composition
- amino acid
- parts
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 112
- 239000000203 mixture Substances 0.000 title claims abstract description 103
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 235000013376 functional food Nutrition 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title abstract description 3
- 229940024606 amino acid Drugs 0.000 claims abstract description 114
- 235000001014 amino acid Nutrition 0.000 claims abstract description 111
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 42
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 24
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 24
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 16
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 16
- 102000007469 Actins Human genes 0.000 claims abstract description 15
- 108010085238 Actins Proteins 0.000 claims abstract description 15
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 15
- 210000004369 blood Anatomy 0.000 claims abstract description 15
- 239000008280 blood Substances 0.000 claims abstract description 15
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 13
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 13
- 238000002512 chemotherapy Methods 0.000 claims abstract description 13
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims abstract description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 12
- 229930064664 L-arginine Natural products 0.000 claims abstract description 12
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 12
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 12
- 229930195722 L-methionine Natural products 0.000 claims abstract description 12
- 239000004473 Threonine Substances 0.000 claims abstract description 12
- 229960002885 histidine Drugs 0.000 claims abstract description 12
- 229960004452 methionine Drugs 0.000 claims abstract description 12
- 229960002898 threonine Drugs 0.000 claims abstract description 12
- 229960004295 valine Drugs 0.000 claims abstract description 12
- 229960003067 cystine Drugs 0.000 claims abstract description 11
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 9
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 11
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 11
- 239000004474 valine Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 230000000153 supplemental effect Effects 0.000 claims description 4
- 230000000091 immunopotentiator Effects 0.000 claims description 2
- 239000012744 reinforcing agent Substances 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 3
- 239000000463 material Substances 0.000 abstract description 10
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 abstract description 8
- 230000009471 action Effects 0.000 abstract description 7
- 238000009169 immunotherapy Methods 0.000 abstract description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 abstract 1
- 235000019393 L-cystine Nutrition 0.000 abstract 1
- 239000004158 L-cystine Substances 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- 229930182844 L-isoleucine Natural products 0.000 abstract 1
- 235000019454 L-leucine Nutrition 0.000 abstract 1
- 239000004395 L-leucine Substances 0.000 abstract 1
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- 229960003136 leucine Drugs 0.000 abstract 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 abstract 1
- 229960004799 tryptophan Drugs 0.000 abstract 1
- 229960004441 tyrosine Drugs 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 25
- 230000000694 effects Effects 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- VIEUIBSXXCVYNO-UHFFFAOYSA-N acetonitrile isothiocyanatobenzene Chemical compound C(C)#N.C1(=CC=CC=C1)N=C=S VIEUIBSXXCVYNO-UHFFFAOYSA-N 0.000 description 3
- PVDVPOZEJCXUAM-UHFFFAOYSA-N acetonitrile;n,n-diethylethanamine Chemical compound CC#N.CCN(CC)CC PVDVPOZEJCXUAM-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000037111 immune power Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000030270 breast disease Diseases 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 229940117953 phenylisothiocyanate Drugs 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- -1 phenylamino formyl sulfide amino acid Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
S1 | S2 | S3 | S4 | S5 | S6 | S7 | S8 | S9 | S10 | |
L-精氨酸 | 6.9 | 6.4 | 3.4 | 3.6 | 7 | 5 | 3.5 | 3 | 6.9 | 3.1 |
L-胱氨酸 | 0.9 | 0.8 | 1.3 | 1 | 1.4 | 0.6 | 1.2 | 0.8 | 0.5 | 1.5 |
L-苯丙氨酸 | 1.2 | 1.3 | 3.2 | 3.6 | 1 | 3.8 | 3.9 | 2.8 | 4 | 1.1 |
L-组氨酸 | 3.1 | 3.2 | 4 | 3 | 3.5 | 6.5 | 6.8 | 6.9 | 4.8 | 7 |
L-异亮氨酸 | 15.1 | 18.9 | 17.5 | 15.5 | 16.8 | 17 | 19 | 16.3 | 15 | 18.8 |
L-赖氨酸 | 19 | 16.1 | 15.6 | 18.9 | 15.5 | 15 | 15.1 | 16.8 | 18 | 15.2 |
L-亮氨酸 | 23 | 23.9 | 20.5 | 20.5 | 24 | 21 | 20.4 | 22.1 | 20.1 | 20 |
L-蛋氨酸 | 0.2 | 0.3 | 0.2 | 0.3 | 0.3 | 0.2 | 0.1 | 0.3 | 0.1 | 0.3 |
L-苏氨酸 | 14.1 | 14.6 | 16.9 | 16.5 | 14.2 | 15 | 15.2 | 14.5 | 17 | 14 |
L-缬氨酸 | 13.1 | 13.5 | 15.5 | 15.9 | 13.5 | 13.9 | 13.2 | 14.5 | 13 | 16 |
L-色氨酸 | 1.9 | 0.2 | 0.5 | 1 | 1.8 | 1 | 1.1 | 1.9 | 0.1 | 1.5 |
L-酪氨酸 | 1.5 | 0.8 | 1.4 | 0.2 | 1 | 1 | 0.5 | 0.1 | 0.5 | 1.5 |
C1 | C2 | C3 | C4 | C5 | C6 | C7 | |
L-精氨酸 | - | - | 7 | - | - | - | - |
L-胱氨酸 | - | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
L-苯丙氨酸 | - | 4 | 4 | 4 | 4 | 4 | 4 |
L-组氨酸 | - | - | - | 7 | - | - | 7 |
L-异亮氨酸 | 19 | 19 | 19 | 19 | 19 | 19 | 19 |
L-赖氨酸 | - | 19 | 19 | 19 | 19 | 19 | 19 |
L-亮氨酸 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
L-蛋氨酸 | - | - | - | - | 0.3 | - | 0.3 |
L-苏氨酸 | - | 17 | 17 | 17 | 17 | 17 | 17 |
L-缬氨酸 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
L-色氨酸 | - | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 |
L-酪氨酸 | - | - | - | - | - | 1.5 | - |
动物 | 第0天(克) | 第10天(克) | 第20天(克) | 第30天(克) | |
S1 | 6 | 21.12±1.23 | 21.47±1.34 | 23.1±1.67 | 24.1±1.69 |
S6 | 6 | 21.10±1.43 | 21.84±1.78 | 23.3±1.57 | 24.3±1.85 |
S7 | 6 | 21.04±1.57 | 21.49±1.28 | 23.2±1.73 | 24.4±1.46 |
S8 | 6 | 21.34±1.66 | 21.58±1.55 | 23.6±1.90 | 25.0±1.59 |
S9 | 4 | 21.05±1.53 | 21.43±1.21 | 23.0±1.53 | 24.0±1.36 |
S10 | 4 | 21.32±1.34 | 21.93±1.48 | 23.7±1.39 | 25.1±1.39 |
C1 | 6 | 21.17±1.63 | 20.42±1.67 | 21.6±1.38 | 22.1±1.47 |
C2 | 6 | 21.02±1.29 | 20.25±1.36 | 21.8±1.89 | 22.3±1.84 |
C3 | 6 | 21.15±1.38 | 20.43±1.63 | 21.5±1.75 | 22.6±1.57 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410628908.7A CN104432026B (zh) | 2014-11-10 | 2014-11-10 | 一种氨基酸组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410628908.7A CN104432026B (zh) | 2014-11-10 | 2014-11-10 | 一种氨基酸组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104432026A true CN104432026A (zh) | 2015-03-25 |
CN104432026B CN104432026B (zh) | 2016-05-04 |
Family
ID=52879373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410628908.7A Active CN104432026B (zh) | 2014-11-10 | 2014-11-10 | 一种氨基酸组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104432026B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114947139A (zh) * | 2022-04-28 | 2022-08-30 | 成都尚医信息科技有限公司 | 一种影响肿瘤生长的氨基酸组合物、功能性食品及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1439364A (zh) * | 2003-03-26 | 2003-09-03 | 浙江大学 | 复方肾保护氨基酸组合物及其应用 |
CN103301120A (zh) * | 2013-06-24 | 2013-09-18 | 华仁药业股份有限公司 | 复方氨基酸注射液的制备方法 |
CN103948588A (zh) * | 2014-04-28 | 2014-07-30 | 山东齐都药业有限公司 | 复方氨基酸注射液及其制备工艺 |
-
2014
- 2014-11-10 CN CN201410628908.7A patent/CN104432026B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1439364A (zh) * | 2003-03-26 | 2003-09-03 | 浙江大学 | 复方肾保护氨基酸组合物及其应用 |
CN103301120A (zh) * | 2013-06-24 | 2013-09-18 | 华仁药业股份有限公司 | 复方氨基酸注射液的制备方法 |
CN103948588A (zh) * | 2014-04-28 | 2014-07-30 | 山东齐都药业有限公司 | 复方氨基酸注射液及其制备工艺 |
Non-Patent Citations (2)
Title |
---|
吴乾: "复方氨基酸胶囊在恶性肿瘤化疗中的临床应用", 《中国药物与临床》 * |
杨橹伶: "肠内营养联合复方氨基酸在恶性肿瘤患者化疗中的应用", 《氨基酸和生物资源》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114947139A (zh) * | 2022-04-28 | 2022-08-30 | 成都尚医信息科技有限公司 | 一种影响肿瘤生长的氨基酸组合物、功能性食品及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104432026B (zh) | 2016-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9308259B2 (en) | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance | |
CN101244255B (zh) | 一种胸腺五肽注射液及其用途 | |
US20140017264A1 (en) | Dosage and administration of bispecific scfv conjugates | |
CN107952072B (zh) | 载药载氧杂交蛋白纳米粒的制备方法、载药载氧杂交蛋白纳米粒和应用 | |
FI114011B (fi) | Suonensisäiseen käyttöön tarkoitetun immunoglobuliinin käyttö farmaseuttisen koostumuksen valmistamiseksi syöpäsairauksien hoitamiseksi | |
CN104432026A (zh) | 一种氨基酸组合物及其制备方法和应用 | |
CN101428035A (zh) | 一种盐酸吉西他滨或吉西他滨组合物 | |
CN101317846B (zh) | 一种用于戒毒、镇痛的河豚毒素制剂 | |
CN1429558A (zh) | 甘露聚糖肽注射液及其制备方法和使用方法 | |
CN107303386A (zh) | 一种用于治疗白细胞低下的口服液的制备方法 | |
CN101163716A (zh) | 白细胞介素-6聚乙二醇结合物及其制备方法和应用 | |
CN110483647A (zh) | 一种抗肿瘤多肽及其应用 | |
CN101502651A (zh) | 狂犬病、破伤风双效价人免疫球蛋白及其制备方法 | |
JPH05508769A (ja) | 細胞培養及び治療に有用なβ―アレチン | |
CN105664174A (zh) | Lf-HA-DOX大分子前药复合物及其构建方法和在治疗神经胶质瘤中的应用 | |
CN101381413A (zh) | 一种修饰的重组人内皮抑素及其应用 | |
CN110548133A (zh) | 血红蛋白及血红蛋白衍生物在制备用于提高免疫功能的注射药物制剂方面的用途 | |
CN114558000B (zh) | 一种白花前胡乙素在制备治疗黑色素瘤的药物中的应用 | |
CN114605517B (zh) | 一种具有广谱抗癌作用的多肽lxp-7及其应用 | |
CN101070346A (zh) | 一种制备双功能抗体的方法 | |
CN107233307A (zh) | 一种布洛芬注射液及其制备方法 | |
CN1951962A (zh) | 用于制备抗肿瘤抗体的多肽及其应用 | |
CN101921820A (zh) | 具有活性重组肿瘤特异性凋亡因子的制备方法及其制品的应用 | |
CN105688185A (zh) | 一种用于治疗骨髓增生、骨癌的药物组合物及其用途 | |
CN102335130A (zh) | 抗肿瘤药甲基斑蝥胺注射液的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171110 Address after: Jiaxing City, Zhejiang province Jiashan County 314199 street to No. 52 Wu Lu Luoxing Valley No. 1 building four Room 401 Patentee after: Zhejiang new all benefit health technology Co.,Ltd. Address before: 201203 Shanghai Zhangjiang High Tech Park of Pudong New Area Cailun Road No. 780 4 floor N block Patentee before: YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210323 Address after: 200000 block n, 4th floor, 780 Cailun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai Patentee after: YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY Co.,Ltd. Address before: Room 401, 4th floor, building 1, No.52 guiguwu Road, Luoxing street, Jiashan County, Jiaxing City, Zhejiang Province Patentee before: Zhejiang new all benefit health technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230916 Address after: Building 6, No. 55 Bixi Road, Minhang District, Shanghai, 200000 Patentee after: Shanghai Helicheng Biomedical Technology Co.,Ltd. Address before: 200000 block n, 4th floor, 780 Cailun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai Patentee before: YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY Co.,Ltd. |